This pipeline uses various statistical tests to identify mRNAs whose expression levels correlated to selected clinical features.
Testing the association between 17814 genes and 15 clinical features across 1593 samples, statistically thresholded by Q value < 0.05, 12 clinical features related to at least one genes.
-
3682 genes correlated to 'AGE'.
-
GREB1 , COL18A1 , DUOX2 , LDOC1 , GALNTL1 , ...
-
17229 genes correlated to 'PRIMARY.SITE.OF.DISEASE'.
-
KLHL14 , ZG16 , SLC22A2 , FOXE1 , PDZD3 , ...
-
10644 genes correlated to 'NEOPLASM.DISEASESTAGE'.
-
SCGB3A2 , MUPCDH , SCGB1A1 , PDZD3 , HNF1A , ...
-
6862 genes correlated to 'PATHOLOGY.T.STAGE'.
-
ADHFE1 , C13ORF3 , NR3C1 , LIFR , RAB6IP1 , ...
-
233 genes correlated to 'PATHOLOGY.N.STAGE'.
-
ARRDC1 , ZCCHC11 , LRFN2 , PBX1 , CACNB3 , ...
-
576 genes correlated to 'PATHOLOGY.M.STAGE'.
-
VIL1 , MUC13 , FABP1 , SPACA3 , ACF , ...
-
8979 genes correlated to 'GENDER'.
-
ESR1 , DDX3Y , RSPO1 , RPS4Y1 , EIF1AY , ...
-
196 genes correlated to 'KARNOFSKY.PERFORMANCE.SCORE'.
-
PPP1R9A , VASN , METTL8 , MARCH7 , ZNF503 , ...
-
17147 genes correlated to 'HISTOLOGICAL.TYPE'.
-
KLHL14 , ZG16 , SLC22A2 , FOXE1 , PDZD3 , ...
-
6320 genes correlated to 'RADIATIONS.RADIATION.REGIMENINDICATION'.
-
CYP3A5 , CYP3A7 , CYP3A4 , MAP2K7 , TCF21 , ...
-
2 genes correlated to 'YEAROFTOBACCOSMOKINGONSET'.
-
MMP10 , ALS2CR4
-
2152 genes correlated to 'COMPLETENESS.OF.RESECTION'.
-
NPR1 , WIT1 , THRSP , KLHL14 , S100A1 , ...
-
No genes correlated to 'Time to Death', 'NUMBERPACKYEARSSMOKED', and 'NUMBER.OF.LYMPH.NODES'.
Complete statistical result table is provided in Supplement Table 1
Clinical feature | Statistical test | Significant genes | Associated with | Associated with | ||
---|---|---|---|---|---|---|
Time to Death | Cox regression test | N=0 | ||||
AGE | Spearman correlation test | N=3682 | older | N=1744 | younger | N=1938 |
PRIMARY SITE OF DISEASE | ANOVA test | N=17229 | ||||
NEOPLASM DISEASESTAGE | ANOVA test | N=10644 | ||||
PATHOLOGY T STAGE | Spearman correlation test | N=6862 | higher stage | N=3197 | lower stage | N=3665 |
PATHOLOGY N STAGE | Spearman correlation test | N=233 | higher stage | N=169 | lower stage | N=64 |
PATHOLOGY M STAGE | ANOVA test | N=576 | ||||
GENDER | t test | N=8979 | male | N=4341 | female | N=4638 |
KARNOFSKY PERFORMANCE SCORE | Spearman correlation test | N=196 | higher score | N=92 | lower score | N=104 |
HISTOLOGICAL TYPE | ANOVA test | N=17147 | ||||
RADIATIONS RADIATION REGIMENINDICATION | t test | N=6320 | yes | N=3013 | no | N=3307 |
NUMBERPACKYEARSSMOKED | Spearman correlation test | N=0 | ||||
YEAROFTOBACCOSMOKINGONSET | Spearman correlation test | N=2 | higher yearoftobaccosmokingonset | N=0 | lower yearoftobaccosmokingonset | N=2 |
COMPLETENESS OF RESECTION | ANOVA test | N=2152 | ||||
NUMBER OF LYMPH NODES | Spearman correlation test | N=0 |
Time to Death | Duration (Months) | 0.1-234.2 (median=25.6) |
censored | N = 990 | |
death | N = 456 | |
Significant markers | N = 0 |
AGE | Mean (SD) | 61.39 (13) |
Significant markers | N = 3682 | |
pos. correlated | 1744 | |
neg. correlated | 1938 |
SpearmanCorr | corrP | Q | |
---|---|---|---|
GREB1 | -0.2892 | 9.188e-32 | 1.64e-27 |
COL18A1 | -0.2758 | 6.342e-29 | 1.13e-24 |
DUOX2 | 0.2752 | 8.485e-29 | 1.51e-24 |
LDOC1 | -0.2683 | 2.09e-27 | 3.72e-23 |
GALNTL1 | -0.267 | 3.747e-27 | 6.67e-23 |
OBSL1 | -0.2642 | 1.335e-26 | 2.38e-22 |
FOXF1 | 0.2611 | 5.404e-26 | 9.62e-22 |
CYP2C18 | 0.2585 | 1.69e-25 | 3.01e-21 |
NOTCH2 | -0.2559 | 5.25e-25 | 9.35e-21 |
BBOX1 | -0.2557 | 5.714e-25 | 1.02e-20 |
PRIMARY.SITE.OF.DISEASE | Labels | N |
BREAST | 526 | |
COLON | 152 | |
ENDOMETRIAL | 54 | |
KIDNEY | 72 | |
LUNG | 186 | |
OMENTUM | 2 | |
OVARY | 529 | |
PERITONEUM OVARY | 2 | |
RECTUM | 68 | |
Significant markers | N = 17229 |
ANOVA_P | Q | |
---|---|---|
KLHL14 | 0 | 0 |
ZG16 | 0 | 0 |
SLC22A2 | 0 | 0 |
FOXE1 | 0 | 0 |
PDZD3 | 0 | 0 |
EMX2 | 0 | 0 |
NPR1 | 0 | 0 |
FUT4 | 0 | 0 |
ACF | 0 | 0 |
FXYD2 | 0 | 0 |
NEOPLASM.DISEASESTAGE | Labels | N |
STAGE I | 133 | |
STAGE IA | 69 | |
STAGE IB | 78 | |
STAGE II | 28 | |
STAGE IIA | 258 | |
STAGE IIB | 145 | |
STAGE III | 24 | |
STAGE IIIA | 102 | |
STAGE IIIB | 52 | |
STAGE IIIC | 39 | |
STAGE IV | 57 | |
STAGE IVA | 1 | |
STAGE TIS | 1 | |
STAGE X | 16 | |
Significant markers | N = 10644 |
ANOVA_P | Q | |
---|---|---|
SCGB3A2 | 2.669e-87 | 4.76e-83 |
MUPCDH | 1.832e-82 | 3.26e-78 |
SCGB1A1 | 6.483e-82 | 1.15e-77 |
PDZD3 | 1.151e-81 | 2.05e-77 |
HNF1A | 5.755e-81 | 1.03e-76 |
CLRN3 | 6.716e-81 | 1.2e-76 |
SFTPB | 1.454e-80 | 2.59e-76 |
SFTPA1 | 2.215e-80 | 3.94e-76 |
SFTPC | 7.77e-80 | 1.38e-75 |
LRRC19 | 8.924e-80 | 1.59e-75 |
PATHOLOGY.T.STAGE | Mean (SD) | 2.11 (0.81) |
N | ||
1 | 225 | |
2 | 490 | |
3 | 237 | |
4 | 51 | |
Significant markers | N = 6862 | |
pos. correlated | 3197 | |
neg. correlated | 3665 |
SpearmanCorr | corrP | Q | |
---|---|---|---|
ADHFE1 | -0.4255 | 2.223e-45 | 3.96e-41 |
C13ORF3 | 0.4162 | 2.734e-43 | 4.87e-39 |
NR3C1 | -0.411 | 3.769e-42 | 6.71e-38 |
LIFR | -0.4037 | 1.361e-40 | 2.42e-36 |
RAB6IP1 | -0.4005 | 6.273e-40 | 1.12e-35 |
C1ORF165 | -0.4004 | 6.532e-40 | 1.16e-35 |
SLC26A6 | 0.3905 | 7.07e-38 | 1.26e-33 |
TBRG4 | 0.3861 | 5.202e-37 | 9.26e-33 |
C19ORF21 | 0.3856 | 6.539e-37 | 1.16e-32 |
EBP | 0.3846 | 1.026e-36 | 1.83e-32 |
PATHOLOGY.N.STAGE | Mean (SD) | 0.63 (0.84) |
N | ||
0 | 545 | |
1 | 260 | |
2 | 121 | |
3 | 34 | |
Significant markers | N = 233 | |
pos. correlated | 169 | |
neg. correlated | 64 |
SpearmanCorr | corrP | Q | |
---|---|---|---|
ARRDC1 | 0.2091 | 6.051e-11 | 1.08e-06 |
ZCCHC11 | -0.2058 | 1.214e-10 | 2.16e-06 |
LRFN2 | 0.2033 | 2.041e-10 | 3.64e-06 |
PBX1 | 0.2028 | 2.26e-10 | 4.03e-06 |
CACNB3 | 0.202 | 2.701e-10 | 4.81e-06 |
HIST1H2AG | 0.1969 | 7.595e-10 | 1.35e-05 |
RPL5 | -0.196 | 9.078e-10 | 1.62e-05 |
MMP11 | 0.1947 | 1.191e-09 | 2.12e-05 |
SPDEF | 0.1937 | 1.451e-09 | 2.58e-05 |
ERRFI1 | -0.1903 | 2.799e-09 | 4.98e-05 |
PATHOLOGY.M.STAGE | Labels | N |
CM0 (I+) | 2 | |
M0 | 925 | |
M1 | 58 | |
M1A | 1 | |
MX | 14 | |
Significant markers | N = 576 |
ANOVA_P | Q | |
---|---|---|
VIL1 | 8.478e-13 | 1.51e-08 |
MUC13 | 2.841e-12 | 5.06e-08 |
FABP1 | 4.306e-12 | 7.67e-08 |
SPACA3 | 4.683e-12 | 8.34e-08 |
ACF | 7.447e-12 | 1.33e-07 |
CALML4 | 7.796e-12 | 1.39e-07 |
TMEM25 | 8.062e-12 | 1.44e-07 |
IL22RA1 | 8.786e-12 | 1.56e-07 |
PCLKC | 1.225e-11 | 2.18e-07 |
PDZD3 | 1.317e-11 | 2.35e-07 |
GENDER | Labels | N |
FEMALE | 1304 | |
MALE | 289 | |
Significant markers | N = 8979 | |
Higher in MALE | 4341 | |
Higher in FEMALE | 4638 |
T(pos if higher in 'MALE') | ttestP | Q | AUC | |
---|---|---|---|---|
ESR1 | -35.87 | 9.367e-164 | 1.67e-159 | 0.8775 |
DDX3Y | 53.23 | 5.05e-163 | 9e-159 | 0.9837 |
RSPO1 | -31.07 | 4.803e-162 | 8.56e-158 | 0.8428 |
RPS4Y1 | 51.71 | 2.642e-155 | 4.71e-151 | 0.9711 |
EIF1AY | 49.21 | 1.083e-151 | 1.93e-147 | 0.9842 |
RPS4Y2 | 48.53 | 1.689e-147 | 3.01e-143 | 0.9814 |
ERBB4 | -32.57 | 2.549e-147 | 4.54e-143 | 0.8586 |
JARID1D | 44.6 | 2.007e-146 | 3.57e-142 | 0.9767 |
SCGB2A2 | -29.39 | 1.805e-145 | 3.21e-141 | 0.8531 |
CYORF15A | 43.7 | 2.34e-139 | 4.17e-135 | 0.981 |
196 genes related to 'KARNOFSKY.PERFORMANCE.SCORE'.
KARNOFSKY.PERFORMANCE.SCORE | Mean (SD) | 60.22 (34) |
Significant markers | N = 196 | |
pos. correlated | 92 | |
neg. correlated | 104 |
SpearmanCorr | corrP | Q | |
---|---|---|---|
PPP1R9A | 0.591 | 4.461e-10 | 7.95e-06 |
VASN | 0.5685 | 2.77e-09 | 4.93e-05 |
METTL8 | -0.5495 | 1.168e-08 | 0.000208 |
MARCH7 | -0.5488 | 1.234e-08 | 0.00022 |
ZNF503 | 0.5415 | 2.087e-08 | 0.000372 |
ADK | -0.5406 | 2.225e-08 | 0.000396 |
PCYT1A | -0.5405 | 2.235e-08 | 0.000398 |
INSIG2 | -0.5394 | 2.423e-08 | 0.000432 |
ARHGEF17 | 0.5392 | 2.453e-08 | 0.000437 |
POGZ | 0.5364 | 2.984e-08 | 0.000531 |
HISTOLOGICAL.TYPE | Labels | N |
COLON ADENOCARCINOMA | 129 | |
COLON MUCINOUS ADENOCARCINOMA | 22 | |
ENDOMETRIOID ENDOMETRIAL ADENOCARCINOMA | 41 | |
INFILTRATING DUCTAL CARCINOMA | 448 | |
INFILTRATING LOBULAR CARCINOMA | 41 | |
KIDNEY CLEAR CELL RENAL CARCINOMA | 72 | |
LUNG ADENOCARCINOMA MIXED SUBTYPE | 1 | |
LUNG ADENOCARCINOMA- NOT OTHERWISE SPECIFIED (NOS) | 30 | |
LUNG BASALOID SQUAMOUS CELL CARCINOMA | 5 | |
LUNG CLEAR CELL ADENOCARCINOMA | 1 | |
LUNG PAPILLARY SQUAMOUS CELL CARICNOMA | 1 | |
LUNG SQUAMOUS CELL CARCINOMA- NOT OTHERWISE SPECIFIED (NOS) | 148 | |
MEDULLARY CARCINOMA | 1 | |
MIXED HISTOLOGY (PLEASE SPECIFY) | 12 | |
MIXED SEROUS AND ENDOMETRIOID | 1 | |
MUCINOUS CARCINOMA | 2 | |
OTHER SPECIFY | 21 | |
RECTAL ADENOCARCINOMA | 58 | |
RECTAL MUCINOUS ADENOCARCINOMA | 7 | |
SEROUS CYSTADENOCARCINOMA | 533 | |
SEROUS ENDOMETRIAL ADENOCARCINOMA | 12 | |
Significant markers | N = 17147 |
ANOVA_P | Q | |
---|---|---|
KLHL14 | 0 | 0 |
ZG16 | 0 | 0 |
SLC22A2 | 0 | 0 |
FOXE1 | 0 | 0 |
PDZD3 | 0 | 0 |
EMX2 | 0 | 0 |
NPR1 | 0 | 0 |
FUT4 | 0 | 0 |
ACF | 0 | 0 |
FXYD2 | 0 | 0 |
6320 genes related to 'RADIATIONS.RADIATION.REGIMENINDICATION'.
RADIATIONS.RADIATION.REGIMENINDICATION | Labels | N |
NO | 200 | |
YES | 1393 | |
Significant markers | N = 6320 | |
Higher in YES | 3013 | |
Higher in NO | 3307 |
T(pos if higher in 'YES') | ttestP | Q | AUC | |
---|---|---|---|---|
CYP3A5 | 23.52 | 2.771e-88 | 4.94e-84 | 0.7943 |
CYP3A7 | 21.91 | 8.376e-80 | 1.49e-75 | 0.7779 |
CYP3A4 | 21.54 | 1.725e-78 | 3.07e-74 | 0.7772 |
MAP2K7 | 22.94 | 8.253e-76 | 1.47e-71 | 0.8166 |
TCF21 | 22.22 | 2.03e-74 | 3.62e-70 | 0.7998 |
REG1A | 20.69 | 4.016e-70 | 7.15e-66 | 0.7827 |
CCDC71 | 22.16 | 3.345e-69 | 5.96e-65 | 0.8246 |
CHMP4B | 21.75 | 6.838e-67 | 1.22e-62 | 0.8239 |
AADAC | 20.1 | 1.341e-65 | 2.39e-61 | 0.7696 |
PDZD3 | 17.97 | 5.585e-64 | 9.94e-60 | 0.6956 |
NUMBERPACKYEARSSMOKED | Mean (SD) | 53.05 (35) |
Significant markers | N = 0 |
YEAROFTOBACCOSMOKINGONSET | Mean (SD) | 1959.74 (11) |
Significant markers | N = 2 | |
pos. correlated | 0 | |
neg. correlated | 2 |
2152 genes related to 'COMPLETENESS.OF.RESECTION'.
COMPLETENESS.OF.RESECTION | Labels | N |
R0 | 403 | |
R1 | 38 | |
R2 | 36 | |
RX | 8 | |
Significant markers | N = 2152 |
-
Expresson data file = PANCAN12-TP.medianexp.txt
-
Clinical data file = PANCAN12-TP.merged_data.txt
-
Number of patients = 1593
-
Number of genes = 17814
-
Number of clinical features = 15
For survival clinical features, Wald's test in univariate Cox regression analysis with proportional hazards model (Andersen and Gill 1982) was used to estimate the P values using the 'coxph' function in R. Kaplan-Meier survival curves were plot using the four quartile subgroups of patients based on expression levels
For continuous numerical clinical features, Spearman's rank correlation coefficients (Spearman 1904) and two-tailed P values were estimated using 'cor.test' function in R
For multi-class clinical features (ordinal or nominal), one-way analysis of variance (Howell 2002) was applied to compare the log2-expression levels between different clinical classes using 'anova' function in R
For two-class clinical features, two-tailed Student's t test with unequal variance (Lehmann and Romano 2005) was applied to compare the log2-expression levels between the two clinical classes using 't.test' function in R
For multiple hypothesis correction, Q value is the False Discovery Rate (FDR) analogue of the P value (Benjamini and Hochberg 1995), defined as the minimum FDR at which the test may be called significant. We used the 'Benjamini and Hochberg' method of 'p.adjust' function in R to convert P values into Q values.
In addition to the links below, the full results of the analysis summarized in this report can also be downloaded programmatically using firehose_get, or interactively from either the Broad GDAC website or TCGA Data Coordination Center Portal.